MTAP and non-small cell lung carcinoma: Given the potential of PRMT5 inhibition in NSCLC and the above‐described interconnection between PRTM5, MTAP, and CDKN2A,10 we examined the genomic alterations occurring in MTAP‐deleted NSCLC cases and assessed the clinical implications of MTAP loss on established predictive and prognostic biomarkers.